Disease Detail

ID DOID:80202
Name adenoid cystic carcinoma
Definition An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer oropharynx cancer tonsil cancer adenoid cystic carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Dovitinib adenoid cystic carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02098538 Phase II Regorafenib Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Active, not recruiting
NCT02780310 Phase II Lenvatinib Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Active, not recruiting
NCT03087019 Phase II Pembrolizumab Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Active, not recruiting
NCT03172624 Phase II Ipilimumab + Nivolumab Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Recruiting
NCT03691207 Phase II BMS-906024 A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY) Recruiting
NCT03990571 Phase II Avelumab + Axitinib Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma Not yet recruiting